The first and potent CXCR4 antagonist, Plerixafor, is Food and Drug Administration (FDA) approved for Stem Cell Mobilization in patients with Multiple Myeloma and Non-Hodgkin lymphoma. This evidence concerns the gene CXCR4 and AL amyloidosis.